Physician
NJ Pain & Spine PC
NJ Pain & Spine PC was paid $4.88M by Medicaid between Jan 2018 and Dec 2024, across 58 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 25% of everything it billed.
33Billing provider infoNJ PAIN & SPINE PC
CLIFTON, NJ 07013
CLIFTON, NJ 07013
33aNPI1033497714assigned 07/28/2011
33bProvider typePain Medicine (Anesthesiology) Physician
28Total paid$4.88M
24GClaims145,260
24DCodes billed58
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pain Medicine (Anesthesiology) Physician providers in New Jersey
Rank by total paid#3 of 35
Median peer was paid$38K
This provider vs. median129×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,464 | $119K | |
| 2019 | 7,199 | $335K | |
| 2020 | 7,913 | $337K | |
| 2021 | 11,122 | $445K | |
| 2022 | 32,019 | $1.27M | |
| 2023 | 57,029 | $1.59M | |
| 2024incomplete | 27,514 | $781K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 25% | 26,924 | 20,019 | $1.24M |
| 64450 | 20% | 18,659 | 9,942 | $994K | |
| J3490 | Unclassified drugs | 19% | 19,727 | 9,773 | $946K |
| 76942 | 5.4% | 12,279 | 9,213 | $265K | |
| 20553 | 4.1% | 14,506 | 9,856 | $198K | |
| L0648 | Lumbar-sacral orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf | 3.5% | 655 | 543 | $169K |
| 64418 | 3.0% | 5,036 | 3,247 | $147K | |
| 64483 | 2.7% | 1,639 | 1,355 | $130K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.9% | 1,249 | 1,120 | $92K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 1.8% | 1,213 | 1,113 | $90K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.8% | 2,361 | 600 | $90K |
| 95913 | 1.3% | 502 | 433 | $64K |
46 more codes
| 64484 | 1.1% | 1,645 | $54K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,671 | $44K |
| E0745 | Neuromuscular stimulator, electronic shock unit | <1% | 174 | $36K |
| 62321 | <1% | 577 | $36K | |
| 77003 | <1% | 4,401 | $35K | |
| 95886 | <1% | 566 | $31K | |
| 95887 | <1% | 566 | $23K | |
| 97124 | <1% | 8,510 | $19K | |
| 62323 | <1% | 358 | $18K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,857 | $18K |
| 64493 | <1% | 311 | $17K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 4,163 | $15K |
| E0731 | Form fitting conductive garment for delivery of tens or nmes (with conductive fibers separated from the patient's skin by layers of fabric) | <1% | 162 | $14K |
| 20610 | <1% | 735 | $12K | |
| 64405 | <1% | 5,806 | $11K | |
| 64495 | <1% | 334 | $11K | |
| Q4206 | Fluid flow or fluid gf, 1 cc | <1% | 20 | $10K |
| 64494 | <1% | 300 | $9K | |
| 80305 | <1% | 1,349 | $8K | |
| 72275 | <1% | 156 | $7K | |
| 97161 | <1% | 314 | $4K | |
| 95912 | <1% | 30 | $4K | |
| 95911 | <1% | 25 | $4K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 36 | $4K |
| 77002 | <1% | 97 | $4K | |
| 72100 | <1% | 83 | $2K | |
| G0281 | Electrical stimulation, (unattended), to one or more areas, for chronic stage iii and stage iv pressure ulcers, arterial ulcers, diabetic ulcers, and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional care, as part of a therapy plan of care | <1% | 903 | $2K |
| 72040 | <1% | 71 | $1K | |
| 64635 | <1% | 13 | $1K | |
| 96130 | <1% | 145 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 293 | $1K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 763 | $824.11 |
| 64636 | <1% | 13 | $780.76 | |
| 97014 | <1% | 355 | $581.66 | |
| 73560 | <1% | 21 | $387.98 | |
| 99443 | <1% | 14 | $271.04 | |
| 97750 | <1% | 50 | $221.95 | |
| 96136 | <1% | 149 | $214.98 | |
| 99358 | Prolong nursin fac eval 15m | <1% | 72 | $136.34 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 283 | $89.47 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 553 | $36.01 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 226 | $14.09 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 75 | $1.12 |
| G0460 | Autologous platelet rich plasma or other blood-derived product for non-diabetic chronic wounds/ulcers, including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration and dressings, per treatment | 0% | 78 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 149 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 38 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHEIKH, EDNAN (CEO)
| Provider | Location | Paid |
|---|---|---|
| Pinnacle Medical Group LLC | Clifton, NJ | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.